Kidney cancers represent approximately seven percent of all cancer diagnoses among children. Although the overall survival rates have significantly increased, certain high risk subgroups still have a very poor prognosis. The molecular mechanisms underlying the high-risk cases are unknown and the focus of the research of Jarno Drost. Pediatric kidney cancer-derived organoids will be established and used for genetic characterization, drug discovery and the development of assays predicting treatment outcome.

The lecture takes place as part of the IRI-Schering Colloquium on “Organoids – Life in 3D,” which is offered at the IRI Life Sciences during the 2018 summer semester.